BRIDGEWATER, N.J. – Martina M. Flammer, the Chief Medical Officer at Insmed Incorporated (NASDAQ: INSM), reported the execution of stock transactions on July 6, 2026, involving the sale of company equity. The total value of the shares sold amounted to approximately $1.35 million. These dispositions were carried out pursuant to a pre-arranged 10b5-1 trading plan, which was initially adopted on February 27, 2025.
Dr. Flammer divested a total of 12,302 shares of Insmed common stock. The execution prices for these shares ranged between $108.90 and $110.71 per share. The aggregate value of the sale was recorded at $1,352,931. Following these transactions, the stock price had advanced to $116.54, supporting a corporate market capitalization of $25.35 billion. Independent analysis from InvestingPro suggests that Insmed’s current valuation may be elevated relative to its calculated fair value. Despite this assessment, a consensus among analysts points to a potential upside of 77%. The biopharmaceutical entity has reported significant revenue expansion of 115% over the preceding twelve months. However, InvestingPro Tips indicate that analysts do not project profitability for the current fiscal year. The platform offers additional ProTips and comprehensive analysis through its detailed Pro Research Report.
Simultaneously with the sales, Dr. Flammer acquired 12,302 shares of Insmed common stock through the exercise of stock options. The acquisition prices for these shares varied between $19.74 and $29.13 per share, resulting in a total value of $317,445. The vesting schedule for these options dictates that 25% of the shares become exercisable on the first anniversary of the grant date. An additional 12.5% vest on each sixth-month anniversary date thereafter, continuing through the fourth anniversary of the grant date.
After completing these transactions, Dr. Flammer’s direct holding of Insmed common stock stands at 60,486 shares.
In concurrent corporate developments, Insmed has announced changes to its executive leadership structure. The company named Samuele Butera as Senior Vice President and General Manager of Global Respiratory. This appointment is intended to reinforce the organization’s strategic focus on its Respiratory Therapeutic Area.
Financial institutions have recently adjusted their outlooks on Insmed stock. Mizuho lowered its price target to $192 from $202, citing volatility concerns and increased investor inquiries ahead of second-quarter results for Brinsupri, Insmed’s lead asset. RBC Capital also reduced its price target to $195 from $205, following discussions with a key opinion leader and Insmed management. Truist Securities decreased its price target to $185 from $205, incorporating competitive risks and adjustments to their financial model post first-quarter 2026 results. Cantor Fitzgerald maintained its Overweight rating and a price target of $235, highlighting the potential of Insmed’s TPIP data in pulmonary arterial hypertension.
Market data indicates Insmed’s stock closed at 116.54, reflecting a gain of 3.70 or 3.28%. After-hours trading showed a decline to 115.28, representing a drop of 1.25 or 1.07. The article notes that this content was generated with AI support and reviewed by an editor. Investors are encouraged to review strategies through ProPicks AI, which evaluates INSM against thousands of alternatives using over 100 financial metrics. The platform claims to have identified Siemens Energy and Sandisk before broader market recognition. A promotional offer for a July sale of InvestingPro is mentioned.